Lintzeris N, et al. - Researchers examined if illicit cannabis use in patients with cannabis dependence who are seeking treatment could be safely and effectively reduced using cannabinoid agonist treatment combined with psychosocial services. For this 12-week, multisite outpatient study, they recruited 128 participants from four outpatient specialist alcohol and drug treatment services in New South Wales, Australia in this parallel double-blind randomized clinical trial comparing nabiximols (a combination of tetrahydrocannabinol and cannabidiol) vs placebo. Outcomes revealed significantly fewer days of illicit cannabis use in correlation to nabiximols vs placebo. Furthermore, participants tolerated nabiximols well, supporting their safety in these patients.